Synthetic Biologics, Inc.
BioTech/Drugs - Rockville, MD, US
Synthetic Biologics, Inc. Employees
Synthetic Biologics, Inc. Senior Management
Steven Shallcross
Chief Executive Officer, Chief Financial Officer and Director
Synthetic Biologics, Inc. Details
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and (2) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), antibiotic-associated diarrhea (AAD) and the emergence of antimicrobial-resistance (AMR). The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU).
Synthetic Biologics, Inc. Technologies
Captcha
reCAPTCHA
Email Providers
Rackspace Email
Marketing Automation
Hatchbuck
Hosting
Amazon AWS
Other
Mobile Friendly
Analytics and Tracking
Google Analytics